| Similar Articles |
|---|
 |
Chemistry World
August 2011
Bibiana Campos Seijo |
Editorial: Heroes and heroin Science dream team... Heroin vaccine...   |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
Smithsonian
April 2007
Eric Jaffe |
The Nic Fix Put down your lighters and pick up your health care cards -- nicotine vaccines are in the works |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
Chemistry World
July 2010 |
Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon |
The Motley Fool
June 29, 2010
Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
Chemistry World
June 2011 |
Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress |
The Motley Fool
April 26, 2011
Luke Timmerman |
FDA Says Vertex Drug a Wee Bit More Effective Than Advertised; Stock Climbs Good news for Vertex? |
The Motley Fool
September 14, 2010
Brian Orelli |
42% Drop? Really? Tell Us Something We Didn't Know. Arena Pharmaceuticals gets knocked down for no good reason. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
Chemistry World
February 7, 2011
Carl Saxton |
Targeting memory loss A new treatment for Alzheimer's disease has been developed by Canadian and US scientists. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Nicotine Addiction: What Lights Up the Field The market for anti-smoking products exceeds $2 billion, but their superiority over cold-turkey quitting remains controversial. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
Chemistry World
July 12, 2012 |
Drawing on drugs to kick the habit While pharma companies stand accused of giving up on drugs to help people stop smoking, tobacco firms are looking at controversial nicotine replacement products. Anthony King surveys an area that is problematic on all sides. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Chemistry World
March 17, 2011
Hepeng Jia |
International recognition helps Chinese vaccine industry Vaccines made in China will now be supplied through United Nations agencies to developing countries, after recognition from the World Health Organisation that China's State Food and Drug Administration has complied with international standards for vaccine regulation. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
BusinessWeek
May 27, 2010
Michelle Cortez |
Karo Bio's Prescription: Cheaper Drug Approval A Swedish company seeks a lower-cost review for its cholesterol drug. |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
March 17, 2011
Brian Orelli |
Taking a Bite Out of Amylin's Obesity Drug Potential Amylin Pharmaceuticals and Takeda announce they were putting a hold on the development of their obesity drug combination pramlintide/metreleptin due to safety issues. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
BusinessWeek
June 2, 2011
Kresge & Connolly |
A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies. |
American Family Physician
July 15, 2003
Evans et al. |
Quantum Sufficit Toilet training can take longer if a child is not ready... Vaccines to treat drug addiction?... A very-low-carbohydrate diet is effective for short-term weight loss in obese women who are otherwise healthy.... Tattooing and body piercing may increase the risk of serious infections... etc. |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
March 28, 2011
Brian Orelli |
Investors Jump for Yervoy! The Food and Drug Administration approval of Bristol-Myers Squibb's Yervoy came with some surprising labeling news. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
